Imaging biomarkers are needed for assessing treatment response in hepatocellular carcinoma (HCC). We evaluated BOLD MRI with hyperoxic challenge in an orthotopic rodent model of HCC for animals treated with the widely used kinase inhibitor sorafenib. A reduction in ΔT2* in tumor and background liver was exhibited for rats treated with sorafenib relative to untreated controls, while no significant change was observed in skeletal muscle. These results demonstrate that BOLD MRI could be a useful tool for detecting treatment effects in HCC.
This abstract and the presentation materials are available to members only; a login is required.